<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881682</url>
  </required_header>
  <id_info>
    <org_study_id>IVITOC 1.1</org_study_id>
    <nct_id>NCT04881682</nct_id>
  </id_info>
  <brief_title>Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</brief_title>
  <acronym>IVITOC</acronym>
  <official_title>Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Miltenyi Biomedicine GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled study evaluating safety and efficacy of repeated&#xD;
      immunoadsorption versus immunoglobulins in steroid-refractory Chronic Inflammatory&#xD;
      Demyelinating Polyneuropathy (CIDP).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CIDP Score</measure>
    <time_frame>15 weeks</time_frame>
    <description>The CIDP Score is a combined score of Inflammatory Cause and Treatment (INCAT) Disability Score, Oxford Muscle Strength Score, and Vibration Score, with each subscore equally weighted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score</measure>
    <time_frame>15 weeks</time_frame>
    <description>Standard clinical score for CIDP, quantifying disability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxford Muscle Strength Score (Medical Research Council, MRC)</measure>
    <time_frame>15 weeks</time_frame>
    <description>Standard clinical score for evaluation of muscle strength / paresis. Muscle strength is evaluated on a scale between 0/5 (no movement) and 5/5 (full strength) at 8 pre-defined muscles (one proximal and one distal muscle at each extremity).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vibration Score</measure>
    <time_frame>15 weeks</time_frame>
    <description>Standard clinical score for evaluation of pallesthesia, using a 256 Hz tuning fork. The individual perception threshold for vibration sensations on a scale between 0/8 (no perception) and 8/8 (normal perception) will be determined at 4 predefined spots (processus styloideus radii and malleolus lateralis on each side).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CIDP Score</measure>
    <time_frame>1, 7, and 13 weeks</time_frame>
    <description>The CIDP Score is a combined score of Inflammatory Cause and Treatment (INCAT) Disability Score, Oxford Muscle Strength Score, and Vibration Score, with each subscore equally weighted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score</measure>
    <time_frame>1, 7, and 13 weeks</time_frame>
    <description>Standard clinical score for CIDP, quantifying disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Muscle Strength Score (Medical Research Council, MRC)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Standard clinical score for evaluation of muscle strength / paresis. Muscle strength is evaluated on a scale between 0/5 (no movement) and 5/5 (full strength) at 8 pre-defined muscles (one proximal and one distal muscle at each extremity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vibration Score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Standard clinical score for evaluation of pallesthesia, using a 256 Hz tuning fork. The individual perception threshold for vibration sensations on a scale between 0/8 (no perception) and 8/8 (normal perception) will be determined at 4 predefined spots (processus styloideus radii and malleolus lateralis on each side).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Quantifying pain on a Visual Analog Scale between 0 (no pain) and 10 (maximum pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>N20 Latency</measure>
    <time_frame>15 weeks</time_frame>
    <description>N20 latency of Nervus medianus (both sides) in somatosensory evoked potentials (SEPs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P40 Latency</measure>
    <time_frame>15 weeks</time_frame>
    <description>P40 latency of Nervus tibialis (both sides) in somatosensory evoked potentials (SEPs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nerve Conduction Velocity</measure>
    <time_frame>15 weeks</time_frame>
    <description>Nerve conduction velocities of clinically affected nerves as measured by electroneurography (ENG).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life 5 Dimension 5 Levels (EQ-5D-5L)</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Quality of Life Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin A</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Immunoglobulin A serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin G</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Immunoglobulin G serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin M</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Immunoglobulin M serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-1</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Interleukin-1 serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Interleukin-6 serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-contactin-1</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Anti-contactin-1 serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-neurofascin155</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Anti-neurofascin155 serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-contactin-associated-protein1</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Anti-contactin-associated-protein1 serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-neurofascin186</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Anti-neurofascin186 serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-neurofascin140</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Anti-neurofascin140 serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurofilament Light Chain (NfL)</measure>
    <time_frame>1, 7, 13, and 15 weeks</time_frame>
    <description>Neurofilament light chain (NfL) serum levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Response</measure>
    <time_frame>15 weeks</time_frame>
    <description>Share of patients with at least 10% improvement in CIDP score compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>CIDP</condition>
  <arm_group>
    <arm_group_label>Immunoadsorption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cycles of immunoadsorption in week 1, 7, and 13 after randomization. One cycle consists of 5 sessions on 5 consecutive days with processing of the 2-fold plasma volume on the first day and the 2.5-fold plasma volume on consecutive days, using regenerative adsorbers (Therasorb, Miltenyi Biotec, Bergisch Gladbach)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunoglobulins</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 cycles of intravenous immunoglobulins in week 1, 4, 7, 10, and 13 after randomization. The first cycle consists of 5 intravenous applications of immunoglobulins on 5 consecutive days in a dosage of 0.4 g per kg body weight per day. Subsequent cycles consist of 2 intravenous applications of immunoglobulins on 2 consecutive days in a dosage of 0.5 g per kg body weight per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Immunoadsorption</intervention_name>
    <description>see arm/group description</description>
    <arm_group_label>Immunoadsorption</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunoglobulins</intervention_name>
    <description>see arm/group description</description>
    <arm_group_label>Immunoglobulins</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of possible, probable, or definite CIDP (typical or atypical) according to&#xD;
             European Federation of Neurological Societies (EFNS) guidelines&#xD;
&#xD;
          -  Disease duration of 3 years or less&#xD;
&#xD;
          -  Age 18 years or above&#xD;
&#xD;
          -  Previous treatment with methyl-prednisolone and insufficient therapeutic response as&#xD;
             judged by the treating physician, or contraindications against methyl-prednisolone, or&#xD;
             clinically significant side effects under methyl-prednisolone therapy as judged by the&#xD;
             treating physician&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical or laboratory evidence of manifest systemic infection, i.e., C-reactive&#xD;
             protein (CRP) above 20 mg/l, or evidence of nitrite-positive urinary tract infection&#xD;
&#xD;
          -  Intake of angiotensin converting enzyme inhibitor within 1 week before first treatment&#xD;
&#xD;
          -  immunoglobulin A deficiency&#xD;
&#xD;
          -  Other contraindications against immunoadsorption or intravenous immunoglobulins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Dorst, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Dorst, Prof</last_name>
    <phone>+49 731 177 5285</phone>
    <email>johannes.dorst@uni-ulm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology, University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Albert Christian Ludolph, Prof.</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after de-identification (text, tables, and figures), as well as the study protocol will be available. Data will be available beginning 3 months and ending 5 years following article publication. Data will be shared with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve the aims in the approved proposal. Proposals should be directed to johannes.dorst@uni-ulm.de; to gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at https://www.uniklinik-ulm.de/neurologie.html.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>3 months after publication until 5 years after publication</ipd_time_frame>
    <ipd_access_criteria>Data will be shared with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve the aims in the approved proposal.</ipd_access_criteria>
    <ipd_url>https://www.uniklinik-ulm.de/neurologie.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

